What's new?

Sofinnova Partners closes €445M ($540M) oversubscribed late-stage healthcare crossover fund

The pioneering growth capital fund is the largest dedicated to biopharma and medtech companies seeking scale-up financing in Europe With over €2 billion under management, Sofinnova Partners continues its expansion across the entire value chain of life sciences investments, from seed to later-stage PARIS, France – M...

Actelion is going public

 

Actelion and Genentech sign licensing agreement for tezosentan in the US

 

IWT and European Comission support confirm CropDesign's leading position

 

Kosan Biosciences Announces Publication Of Heterologous Expression Of Potential Anti-Cancer Agent, Epothilone, In Science

 

Kosan appoints vice President, Finance/CFO

Hayward CA. -Kosan Biosciences, Inc. announced today that Susan M. Kanaya has joined the company as Vice President, Finance and Chief Financial Officer.

Actelion Announces Recruitment of First Patients in its Phase III Clinical Development Program on Tezosentan in Acute Heart Failure

Allschwil. Actelion Ltd. today announced that it has begun its international Phase III clinical development program on tezosentan for intravenous use in patients with acute heart failure.

1 ... 182 183 184